COVID-19 IMPACT SURVEY MAY 2020
Amid the COVID-19 crisis and the looming economic recession, the Vasculitis Treatment market worldwide will grow by a projected US$132.4 Million, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 4.3%. Biologics, one of the segments analyzed and sized in this study, is forecast to grow at over 4.2% and reach a market size of US$261.6 Million by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Biologics market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.
As part of the new emerging geographic scenario, the United States is forecast to readjust to a 5.1% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$6.3 Million to the region's size over the next 7 to 8 years. In addition, over US$5.9 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Biologics segment will reach a market size of US$20.3 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Vasculitis Treatment market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 4.7% over the next couple of years and add approximately US$23.9 Million in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Vasculitis Treatment market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.
Competitors identified in this market include, among others, AB Science SA; Ablynx NV; Acorda Therapeutics, Inc.; Antares Pharma, Inc.; Astellas Pharma, Inc.; AstraZeneca PLC; Baxter International, Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Can-Fite BioPharma Ltd.; Celgene Corporation; Celltrion Healthcare Co., Ltd.; Coherus BioSciences; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; GlaxoSmithKline PLC; Hospira, Inc.; Idera Pharmaceuticals, Inc.; Immunomedics, Inc.; Incyte Corporation; Lexicon Pharmaceuticals, Inc.; MedImmune LLC; Merck & Co., Inc.; Morphotek, Inc.; Novartis AG; Novo Nordisk A/S; Regeneron Pharmaceuticals, Inc.; Sandoz International GmbH; Sanofi SA; Takeda Pharmaceutical Co., Ltd.; UCB SA; Vertex Pharmaceuticals Inc.